AACR21: As­traZeneca un­veils next-gen PARP in­hibitor, look­ing to fol­low up on suc­cess of first-gen suc­cess sto­ry Lyn­parza

As­traZeneca’s PARP in­hibitor Lyn­parza has raced out to block­buster sales on the premise of killing tu­mor cells by in­hibit­ing their abil­i­ty to ad­e­quate­ly heal. But Lyn­parza isn’t a per­fect mol­e­cule, and the British drug­mak­er is now rolling out a po­ten­tial suc­ces­sor drug it hopes can achieve sim­i­lar ef­fi­ca­cy with­out the no­to­ri­ous side ef­fects.

As­traZeneca rolled out ear­ly da­ta on its PARP1-se­lec­tive, next-gen in­hibitor AZD5305 at the vir­tu­al AACR meet­ing Sat­ur­day, hop­ing to high­light the drug’s chances at fol­low­ing up — and im­prov­ing — the sci­ence be­hind block­buster drug Lyn­parza.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER